301690-20-0

Basic information

• Product Name: 3-[2-(4-tert-butylphenoxy)acetylamino]benzoic acid methyl ester
• Synonyms: 3-[2-(4-tert-butylphenoxy)acetylamino]benzoic acid methyl ester
• CAS NO: 301690-20-0
• Molecular Weight: 341.407
• Mol File: 301690-20-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3-[2-(4-tert-butylphenoxy)acetylamino]benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[2-(4-tert-butylphenoxy)acetylamino]benzoic acid methyl ester(301690-20-0)
• EPA Substance Registry System: 3-[2-(4-tert-butylphenoxy)acetylamino]benzoic acid methyl ester(301690-20-0)

Safety Data

• Hazardous Substances Data: 301690-20-0(Hazardous Substances Data)

Upstream product

• 3344-19-2 4-tert-butyl-phenoxyacetic acid ethyl ester 
• 98-54-4 para-tert-butylphenol 
• 4518-10-9 Methyl 3-aminobenzoate 
• 1798-04-5 (4-tert-butylphenoxy)acetic acid 

Relevant articles and documents

(Aryloxyacetylamino)benzoic acid analogues: A new class of hypoxia-inducible factor-1 inhibitors

Structural modification of a compound discovered during screening using an HRE-dependent reporter assay has revealed a novel class of HIF-1 inhibitors, which potently inhibit the HIF-1α protein accumulation and its target gene expression under hypoxic conditions in human hepatocellular carcinoma Hep3B cells.

Methyl 3-(3-(4-(2,4,4-Trimethylpentan-2-yl)phenoxy)-propanamido)benzoate as a Novel and Dual Malate Dehydrogenase (MDH) 1/2 Inhibitor Targeting Cancer Metabolism

Previously, we reported a hypoxia-inducible factor (HIF)-1 inhibitor LW6 containing an (aryloxyacetylamino)benzoic acid moiety inhibits malate dehydrogenase 2 (MDH2) using a chemical biology approach. Structure-activity relationship studies on a series of (aryloxyacetylamino)benzoic acids identified selective MDH1, MDH2, and dual inhibitors, which were used to study the relationship between MDH enzyme activity and HIF-1 inhibition. We hypothesized that dual inhibition of MDH1 and MDH2 might be a powerful approach to target cancer metabolism and selected methyl-3-(3-(4-(2,4,4-trimethylpentan-2-yl)phenoxy)propanamido)-benzoate (16c) as the most potent dual inhibitor. Kinetic studies revealed that compound 16c competitively inhibited MDH1 and MDH2. Compound 16c inhibited mitochondrial respiration and hypoxia-induced HIF-1α accumulation. In xenograft assays using HCT116 cells, compound 16c demonstrated significant in vivo antitumor efficacy. This finding provides concrete evidence that inhibition of both MDH1 and MDH2 may provide a valuable platform for developing novel therapeutics that target cancer metabolism and tumor growth.

COMPOUNDS TEAT INHIBIT HBF-I ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT

Disclosed herein are an HIF-I inhibitor, a method for the preparation thereof, and a pharmaceutical composition comprising the same as an active ingredient The BDDF-I inhibitor shows anticancer activity thanks to the inhibition activity against HIF-I, a transcription factor which plays an important role in the growth and metastasis of cancer, but not to general cytotoxicity. Thus, the HIF-inhibitor and a pharmaceutically acceptable salt thereof can be used as a therapeutic for various cancers such as liver cancer, stomach cancer and breast cancer. Also, the compound having inhibition activity against HDDF-I is useful in the treatment of diabetic retinopathy and arthritis, which are aggravated by HEF-l-mediated VEGF expression.